tbuckley/cabot-search huggingface dataset:
Cancer drugs remain FDA approved despite lack of benefit, study finds
Authors: Michael McCarthy
Journal: BMJ (2016)

Cancer drugs initially approved by the US Food and Drug Administration on the basis of surrogate endpoints often remain FDA approved even after postmarketing studies find that they neither prolong patients’ lives nor improve their quality of life, a US study has found.

Tracy Rupp and Diana Zuckerman of the National Center for Health Research, a non-profit organization based in Washington, DC, looked at 18 cancer drugs approved by the FDA from 2008 to 2012 on the basis of surrogate endpoints such as tumor shrinkage or progression free survival.1 A previous report showed that postmarketing studies had found that these drugs conferred no overall …
Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers
Authors: Chezi Ganzel, Vikram Mathews, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Deborah Kuk, Sean Devlin, Hailin Wang, Daniel Weisdorf, Dan Douer, Jacob M. Rowe, Arnon Nagler, Mohamad Mohty, Martin S. Tallman, Jordi Estev, Mei-Jie Zhang
Journal: Blood (2015)
Pre-Transplant Low Dose Cyclophosphamide Enhances Engraftment and Immune Reconstitution in Haploidentical Hematopoietic Stem Cell Transplant (HCT) Recipients Receiving Total Body Radiation (TBI) Free Reduced Intensity Conditioning with Post- Transplant Cyclophosphamide (PTCY)
Authors: Yasser Khaled, George Yaghmour, Christy R Parks, Deborah Lamontagne, Joshua Boss, Diwura Owolabi, Sallyanne C. Fossey, Lisa Murphy, Robert Bradley
Journal: Blood (2016)
A Comparison of INNOVANCE® PFA P2Y and VerifyNow P2Y12 Assay for the Assessment of Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention
Authors: Soyoung Shin, Yonggoo Kim, Jihyang Lim, Jiyoung Jang, Jayoung Kim
Journal: Blood (2011)
Recovery of Polyclonal Immunoglobulin Synthesis after Autologous Stem Cell Transplantation in Multiple Myeloma Patients as a Prognostic Factor for Event-Free Survival.
Authors: Annette Höfer, Axel Benner, Jens Klaus, Iris Breitkreutz, Doris Herrmann, Friedrich W. Cremer, Sabine Gerull, Thomas Moehler, Gerlinde Egerer, Ute Hegenbart, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2004)
Fear of cancer recurrence and quality of life among survivors of pancreatic and periampullary neoplasms.
Authors: Maria Q. B. Petzel, Nathan H Parker, Alan D. Valentine, Sebastien Simard, Graciela M Nogueras Gonzalez, Jason B. Fleming, Jeffrey Edwin Lee, Peter W. T. Pisters, Jean-Nicolas Vauthey, Matthew H.G. Katz
Journal: Journal of Clinical Oncology (2012)

289 Background: Fear of Cancer Recurrence (FCR) is well documented among survivors of breast, colon and prostate cancer. Incurable recurrence is common following resection of pancreatic and periampullary neoplasms. The incidence and significance of FCR in this population is unknown. We hypothesized that FCR represents an important source of psychosocial distress following resection of pancreatic neoplasms. Methods: We conducted a cross-sectional study of patients with non-recurrent pancreatic ductal (PDAC), periampullary adenocarcinoma or pancreatic neuroendocrine tumor (PNET) treated with potentially curative surgery 1991–2011. We assessed 7 discrete dimensions of FCR using the Fear of Recurrence Inventory (FCRI) and evaluated quality of life (QOL) and psychosocial distress using the Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire and Hospital Anxiety and Depression Scale. Participants completed these validated instruments by mail. Results: 188 (53%) of 355 eligible patients completed at least one instrument, a median of 49 months (range, 6–222 months) following potentially curative resection. Participants included 73 (39%) patients with PDAC, 55 (29%) with periampullary adenocarcinoma, and 60 (32%) with PNET. The median FCR severity score was higher than a previously established cutoff for clinical significance in 55%, 51% and 63% of patients with PDAC, periampullary adenocarcinoma and PNET, respectively. Older age, male gender, periampullary adenocarcinoma, negative lymph nodes, and longer interval since operation were clinical factors associated with lower total FCR score (all p&lt;0.05). In multivariate analysis, only age (p=0.01) and gender (p=0.03) were independently associated with severity of FCR. A higher total FCR score was significantly associated with higher anxiety (r=0.64), depression (r=0.41) and lower QOL (r =−0.53), all p&lt;0.001. Conclusions: Fear of cancer recurrence is pervasive following resection of pancreatic neoplasms, regardless of survivors’ histopathologic diagnosis, disease severity, or time since resection. Given its association with anxiety, depression and lower QOL, FCR represents a critical therapeutic target.
The Homeobox Gene VENTX Collaborates with AML1-ETO in Inducing an Acute Leukemia in Mice
Authors: Eva Gentner, Naidu Vegi, Medhanie A. Mulaw, Leticia Quintanilla-Fend, Hartmut Döhner, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat, Michaela Feuring-Buske
Journal: Blood (2015)
Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC).
Authors: S. Lee, Y. H. Park, E. Y. Cho, Y. H. Ham, J. J. Seo, J. S. Ahn, Y. Im
Journal: Journal of Clinical Oncology (2011)

1089 Background: TNBC, one of the most aggressive breast cancer subtypes, is of pivotal clinical importance given the lack of therapeutic target. Regulatory T cells (Tregs) including FOXP3 are potent mediators of dominant self tolerance for cancer. However, obscurity as to the identity, stability and suppressive function of Tregs has impeded therapeutic use. Some of TNBCs are thought to be related with immune genes. Interestingly, TNBCs were reported to be associated with higher number of FOXP3 (Bohling et al. Mod Pathol 2008). The aim of this study is to investigate the prognostic significance of FOXP3 in TNBC. Methods: We investigated the number of tumor-infiltrating FOXP3(+) Tregs in formalin-fixed TNBC specimens which patients received palliative treatment in Samsung Medical Center between 1999 and 2007. Immunohistochemistry was used to assess the numbers of CD4(+), CD25(+), and FOXP3(+) Tregs in tumors and normal breast tissues from 86 patients. The number of FOXP3(+) Tregs was calculated as the total number of positive cells per 10 high-power fields (HPF). Univariate and multivariate analyses for survival were performed according to the number of FOXP3(+) Tregs. Results: Of the 86 tumor specimens, 22 (25.6%) were found to express over 15 per 10 HPF for FOXP3(+) Tregs in peritumoral area. Within the invasive tumor samples, there was a significant correlation between FOXP3(+) (≥15) and lymphovascular invasion (P=0.012), extensive intraductal component (P=0.001), metastasis to axillary lymph nodes (P=0.048), and metastasis to pleura (P=0.008). Kaplan-Meier survival curves for OS and progression free survival (PFS) according to FOXP3 expression revealed significant better outcomes for patients with higher staining (≥ 15) than those with lower staining (< 15) (median PFS 4.2 vs 3.0 months, P=0.036; median OS 62 vs 18 months, P=0.036). By multivariate analysis, higher FOXP3(+) tumor staining ≥15 was an independent prognostic factor for OS (P=0.036) with hazard ratios of 0.46 (95% CI, 0.24 to 0.97; P=0.040). Conclusions: The metastatic TNBC patients with higher FOXP3(+) showed significant better outcomes than those with lower FOXP3(+) in terms of PFS and OS. The inclusion of FOXP3(+) may improve the prognositication of TNBC.
High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies
Authors: Yago Nieto, Peter F Thall, Borje S Andersson, Uday R Popat, Paolo Anderlini, Benigno C. Valdez, Elizabeth J Shpall, Muzaffar Qazilbash, Amin M Alousi, Christina Chancoco, Chitra M Hosing, Partow Kebriaei, Qaiser Bashir, Nina Shah, Issa Khouri, Stefan O Ciurea, Becky McMullin, Gabriela Rondon, Richard Champlin, Roy Jones
Journal: Blood (2011)
Consumption of Combustible and Smokeless Tobacco — United States, 2000–2015
Authors: Teresa W. Wang, Brandon Kenemer, Michael A. Tynan, Tushar Singh, Brian King
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Combustible and smokeless tobacco use causes adverse health outcomes, including cardiovascular disease and multiple types of cancer (1,2). Standard approaches for measuring tobacco use include self-reported surveys of use and consumption estimates based on tobacco excise tax data (3,4). To provide the most recently available tobacco consumption estimates in the United States, CDC used federal excise tax data to estimate total and per capita consumption during 2000-2015 for combustible tobacco (cigarettes, roll-your-own tobacco, pipe tobacco, small cigars, and large cigars) and smokeless tobacco (chewing tobacco and dry snuff). During this period, total combustible tobacco consumption decreased 33.5%, or 43.7% per capita. Although total cigarette consumption decreased 38.7%, cigarettes remained the most commonly used combustible tobacco product. Total noncigarette combustible tobacco (i.e., cigars, roll-your-own, and pipe tobacco) consumption increased 117.1%, or 83.8% per capita during 2000-2015. Total consumption of smokeless tobacco increased 23.1%, or 4.2% per capita. Notably, total cigarette consumption was 267.0 billion cigarettes in 2015 compared with 262.7 billion in 2014. These findings indicate that although cigarette smoking declined overall during 2000-2015, and each year from 2000 to 2014, the number of cigarettes consumed in 2015 was higher than in 2014, and the first time annual cigarette consumption was higher than the previous year since 1973. Moreover, the consumption of other combustible and smokeless tobacco products remains substantial. Implementation of proven tobacco prevention interventions (5) is warranted to further reduce tobacco use in the United States.
Genetic Variants Associated with Circulating Parathyroid Hormone
Authors: Cassianne Robinson-Cohen, Pamela L. Lutsey, Marcus E. Kleber, Carrie M. Nielson, Braxton D. Mitchell, Joshua C. Bis, Karen M. Eny, Laura Portas, Joel Eriksson, Mattias Lorentzon, Daniel L. Koller, Yuri Milaneschi, Alexander Teumer, Stefan Pilz, Maria Nethander, Elizabeth Selvin, Weihong Tang, Lu-Chen Weng, Hoi Suen Wong, Dongbing Lai, Munro Peacock, Anke Hannemann, Uwe Völker, Georg Homuth, Matthias Nauk, Federico Murgia, Jack W. Pattee, Eric Orwoll, Joseph M. Zmuda, Jose Antonio Riancho, Myles Wolf, Frances Williams, Brenda Penninx, Michael J. Econs, Kathleen A. Ryan, Claes Ohlsson, Andrew D. Paterson, Bruce M. Psaty, David S. Siscovick, Jerome I. Rotter, Mario Pirastu, Elizabeth Streeten, Winfried März, Caroline Fox, Josef Coresh, Henri Wallaschofski, James S. Pankow, Ian H. de Boer, Bryan Kestenbaum
Journal: Journal of the American Society of Nephrology (2016)

Parathyroid hormone (PTH) is a primary calcium regulatory hormone. Elevated serum PTH concentrations in primary and secondary hyperparathyroidism have been associated with bone disease, hypertension, and in some studies, cardiovascular mortality. Genetic causes of variation in circulating PTH concentrations are incompletely understood. We performed a genome-wide association study of serum PTH concentrations among 29,155 participants of European ancestry from 13 cohort studies ( n =22,653 and n =6502 in discovery and replication analyses, respectively). We evaluated the association of single nucleotide polymorphisms (SNPs) with natural log-transformed PTH concentration adjusted for age, sex, season, study site, and principal components of ancestry. We discovered associations of SNPs from five independent regions with serum PTH concentration, including the strongest association with rs6127099 upstream of CYP24A1 ( P =4.2 × 10 −53 ), a gene that encodes the primary catabolic enzyme for 1,25-dihydroxyvitamin D and 25-dihydroxyvitamin D. Each additional copy of the minor allele at this SNP associated with 7% higher serum PTH concentration. The other SNPs associated with serum PTH concentration included rs4074995 within RGS14 ( P =6.6 × 10 −17 ), rs219779 adjacent to CLDN14 ( P =3.5 × 10 −16 ), rs4443100 near RTDR1 ( P =8.7 × 10 −9 ), and rs73186030 near CASR ( P =4.8 × 10 −8 ). Of these five SNPs, rs6127099, rs4074995, and rs219779 replicated. Thus, common genetic variants located near genes involved in vitamin D metabolism and calcium and renal phosphate transport associated with differences in circulating PTH concentrations. Future studies could identify the causal variants at these loci, and the clinical and functional relevance of these variants should be pursued.
Shifting Approaches for Evaluation of Resident Performance
Authors: Lia S. Logio
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of CXCR-4 and Adhesion Molecule Expression in Healthy Bone Marrow with Expression in Bone Marrow and Peripheral Blood of Patients Receiving G-CSF Plus AMD3100.
Authors: Uta Oelschlaegel, Martin Bornhaeuser, Frank Kroschinsky, Gerhard Ehninger, Uwe Platzbecker
Journal: Blood (2005)
Von Willebrand Factor Protects Factor VIII from Endocytosis by Human Monocytes−Derived Dendritic Cells and Subsequent Presentation to Immune Effectors.
Authors: Yohann Repesse, Suryasarathi Dasgupta, Ana Maria Navarette, Sandrine Delignat, Bharath Wootla, Annie Borel-Derlon, Srinivas V. Kaveri, Sebastien Lacroix-Desmazes
Journal: Blood (2006)
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma?
Authors: G. Procopio, E. Verzoni, R. Iacovelli, V. Guadalupi, N. Nicolai, T. Torelli, D. Biasoni, M. Colecchia, R. Salvioni
Journal: Journal of Clinical Oncology (2011)

396 Background: Carcinoma of Bellini collecting ducts (CDC) is very uncommon but it is one of the most aggressive urological entities. For this tumor, originating from the epithelium of Bellini ducts in the distal tubule and preferentially occurring in young populations, no standard effective therapy has been so far established. Results of previous clinical experiences with chemo- or immunotherapy have been disappointing. We report our experience in 7 cases of CDC treated with targeted therapies. Methods: From December 2004 to May 2010, 333 patients with advanced renal cell carcinoma have been treated with targeted therapies at Istituto Nazionale Tumori of Milan. From the global database analysis, seven cases with histological subtype of CDC have been identified. All patients had advanced disease and received a targeted therapy as first-line treatment. Six of them underwent previous nephrectomy, all had nodal involvement, and three had two or more sites of disease including lung, liver, and adrenal glands. Four patients received sorafenib as first-line treatment, two sunitinib, and one temsirolimus. After sorafenib failure, two patients received a second-line treatment consisting of both sunitinib and temsirolimus. Results: Five patients developed early progression of disease with a very short 4-month survival. One patient had a long term partial response of 33 months with sorafenib, he underwent second-line sunitinib and had no progression for further 10 months. The last patient reached a progression-free survival of 6 months with temsirolimus; when progressed, he achieved a disease control for further 9 months during sunitinib therapy. Both patients are alive after 50 and 15 months of treatment, respectively. The most common adverse events, low or moderate in severity, consisted of fatigue, hand-foot skin reaction, diarrhea, hypertension, and anemia. Conclusions: Prognosis of advanced CDC remains unfavorable. New target agents may be active in this disease and need further prospective phase II studies. [Table: see text]
Monitoring of HIV testing services in the EU/EEA
Authors: Lara Tavoschi, David Hales
Journal: Eurosurveillance (2016)

Preview this article: Monitoring of HIV testing services in the EU/EEA, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/48/eurosurv-21-30410-6-1.gif
Study on the Dendritic Cell Subsets and Their Relationship with the Expressions of T-Bet and GATA-3 in Peripheral Lymphocytes of Severe Aplastic Anemia Patients
Authors: Zonghong Shao, Wang Jun, Rong Fu, Lijuan Li, Hui Liu, Wen Qu, Erbao Rua, Yong Liang, Hong Liu, Yuhong Wu, Guojin Wang, Jia Song, Huaquan Wang, Limin Xing, Jing Guan, Xiaoming Wang
Journal: Blood (2008)
The G20210A Prothrombin Gene Mutation and the Plasminogen Activator Inhibitor (PAI) 844GG Genotype Increase the Risk of Premature Onset of Severe Preeclampsia.
Authors: Andrea Gerhardt, Tamme W. Goecke, Matthias W. Beckmann, Rudiger E. Scharf, Rainer B. Zotz
Journal: Blood (2004)
Risk of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma
Authors: Chia-Jen Liu, Pei Hsu, Ting-Wei Lin, Jyh-Pyng Gau, Liang-Tsai Hsiao, Cheng-Hwai Tzeng, Po-Min Chen, Yuan-Bin Yu, Tzeon-Jye Chiou, Yao-Chung Liu, Jing-Hwang Liu
Journal: Blood (2015)
Enhanced Anti-Myeloma Activity by Combination of Receptor Tyrosine Kinase (RTK) Inhibition, Proteasome Inhibition, and Dexamethasone: Therapeutic Implications for t(4;14) and t(14;16) Multiple Myeloma (MM) Subgroups.
Authors: Guido Bisping, Doris Wenning, Martin H. Kropff, Gerd Munzert, Frank Hilberg, Gerald J. Roth, Wolfgang E. Berdel, Joachim Kienast
Journal: Blood (2005)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Authors: Nitin Jain, Kathryn G. Roberts, Elias Jabbour, Keyur Patel, Agda Karina Eterovic, Ken Chen, Patrick Zweidler-McKay, Xinyan Lu, Gloria Fawcett, Sa A. Wang, Sergej Konoplev, Richard C. Harvey, I-Ming Chen, Debbie Payne-Turner, Marcus Valentine, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Jorge Cortes, Steven Kornblau, Susan O’Brien, Sherry Pierce, Jeffrey Jorgensen, Kenna R. Mills Shaw, Cheryl L. Willman, Charles G. Mullighan, Hagop Kantarjian, Marina Konopleva
Journal: Blood (2016)
A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.
Authors: Pier Luigi Zinzani, Monica Tani, Stefano Fanti, Gerardo Musuraca, Alessio Perrotti, Umberto Vitolo, Mariapaola Fina, Barbara Botto, Enrica Marchi, Giulia Benevolo, Vittorio Stefoni, Michele Baccarani
Journal: Blood (2006)
Role of homeobox pathway in prostate carcinogenesis.
Authors: James Lin Chen, Kristen Otto, Donald Vander Griend
Journal: Journal of Clinical Oncology (2012)

126 Background: Identifying aberrant activity of developmental pathways in prostate cancer provides therapeutic opportunities. To this end, despite a shared embryonic origin and similarities to prostate cancer in histology and androgen dependence, seminal vesicle cancer is exceptionally rare. Genomic pathway analyses of their critical developmental differences may reveal uncharacterized oncogenic pathways. Previous attempts to do so have used whole tissue preparations. We hypothesized that careful gene profiling of pure primary epithelial cultures from normal prostate and seminal vesicles would reduce confounding noise during analysis and provide more robust pathway prioritization. Methods: Paired normal prostate and seminal vesicle epithelium cultures were created from three de-identified patients. Derived gene expression profiles were grouped into cancer biomodules using a protein-protein network algorithm to analyze their relationship to known oncogenes. Each resultant biomodule was assayed for its prognostic ability in independent Kaplan-Meier analyses of prostate cancer patients for time to recurrence and overall survival. Protein products from prioritized biomodule genes were then evaluated in vitro. Results: Gene expression profiling and protein network prioritization resulted in three cancer biomodules. Survival analysis revealed that the embryonic developmental biomodule centered on homeobox genes Meis1, Meis2 and Pbx1 to have clinical import. This homeobox biomodule detected a survival difference in a set of active surveillance patients (n=172, p=0.05) and identified men who were more likely to recur biochemically post-prostatectomy (n=78, p=0.02). We analyzed in vitro protein expression of Meis1, Meis2, Pbx1 and confirmed decreased gene expression in independent datasets of prostate cancer versus normal tissue. Conclusions: The Meis1/Meis2/Pbx1 biomodule may explain key differences in seminal vesicle and normal prostate epithelium development. In contrast to other cancers, Meis1, Meis2, and Pbx1 may play a tumor suppressor role in prostate cancer. Thus deregulation of this biomodule may be critical in prostate cancer oncogenesis.